90y basiliximab - a radioimmunoconjugate composed of basiliximab, a chimeric, mouse human monoclonal antibody directed against the alpha subunit of interleukin 2 receptor (il 2r alpha, cd25 or tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium y 90 basiliximab selectively binds to il 2r alpha expressed on the surface of activated t lymphocytes, thereby preventing il 2 binding and blocking the il 2 mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the il 2 receptor. This may prevent t cell mediated activation of the immune system against a certain transplant and may prevent transplant rejection.
Up to date info
Latest research - 90y basiliximab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 90y basiliximab for any updates.